18:07 ET - Cantor Fitzgerald says it's time to take a look at two antifungal stocks in light of a study from the Centers for Disease Control and Prevention yesterday describing a rare and often deadly fungus spreading rapidly across the US. Candida auris, a fungus discovered about 15 years ago in Japan, infected at least 2,377 people in the US in 2022, up from 53 in 2016, the CDC says. Cantor analysts reiterate their overweight ratings for Cidara Therapeutics and Scynexis with price targets of $5 and $15, respectively. The analysts say they believe both of these companies have potentially positive catalysts in the next 12 to 18 months. Cidara makes Rezafungin and Scynexis makes Ibrexafungerp, and both drugs are designed to fight fungal infections. Cidara shares closed up nearly 12% to $1.98 and Scynexis surged 35% to $1.56.